leadf
logo-loader
viewBiocept Inc

Biocept raises around $10.3 million through a further registered direct share offering with several institutional investors

The firm has entered into a securities purchase agreement for the issuance and sale of 22,300,000 shares of its common stock at a price of $0.46 each

Dollars
The move follows two earlier securities purchase agreement with several institutional investors, also via registered direct offerings, announced at the start of March.

Biocept, Inc. (NASDAQ:BIOC) said Tuesday that it is to raise approximately $10.3 million in aggregate through a further registered direct share offering with several institutional investors.

In a statement, the leading commercial provider of liquid biopsy said it has entered into a securities purchase agreement for the issuance and sale of 22,300,000 shares of its common stock at a price of $0.46 each.

READ: Biocept to begin coronavirus testing in its highly advanced and certified lab in San Diego

The company said Maxim Group is acting as the sole placement agent for the offering, which is expected to close on or about April 16, 2020, subject to the satisfaction of customary closing conditions.

The move follows two earlier securities purchase agreement with several institutional investors, also via registered direct offerings, announced at the start of March.

That saw the issuance and sale of 16 million shares at a price of $0.41 each to raise $6.6 million on March 5 come hot on the heels of a $9.2 million registered direct offering announced on March 2 which saw the issuance and sale of 23 million shares of Biocept common stock at a price of $0.40 per share.

Biocept said then that it expected its current cash and cash equivalents, to be sufficient to fund operations through to at least December 31, 2020, but that was before the coronavirus (COVD-19) pandemic.

On Monday, Biocept revealed that it has verified a coronavirus (COVID-19) molecular diagnostic test, and said it plans to begin accepting physician-ordered testing requests for processing beginning on April 15.

Quick facts: Biocept Inc

Price: 4.86 USD

NASDAQ:BIOC
Market: NASDAQ
Market Cap: $65.11 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Biocept announces Highmark has made a positive coverage determination on...

Biocept (Nasdaq: BIOC) CEO Michael Nall joined Steve Darling from Proactive with news the company has received positive news from Highmark, America’s fourth-largest Blue Cross Shield affiliate. That news being Biocept's Target Selector liquid biopsy assays have been accepted for medical coverage...

on 23/9/20

2 min read